Skip to main content

Table 4 Comparison of prednisolone monotherapy (PM) and prednisolone combined with immunosuppressants/biologics (PC) groups

From: Risk factors for the recurrence of relapsing polychondritis

 

PM

PC

P value

n=23

n=11

Age at onset (years)

52 (45–70)

46 (30–58)

0.1616

Female, n (%)

13 (56.5)

4 (36.4)

0.4646

Disease duration (years)

5.5 (2.9–6.8)

4.5 (1.8–12.9)

0.6720

Time until diagnosis (days)

151 (78–270)

105 (91–235)

0.8684

Time until treatment (days)

151 (78–270)

156 (99–467)

0.6586

Initial symptoms, n (%)

 Auricular

18 (78.3)

5 (45.5)

0.1143

 Tracheobronchial

4 (17.4)

7 (63.6)

0.0160

RPDAI

23 (15–41)

33 (22–35)

0.2851

WBC (/μl)

7000 (5500–8200), n=15

7710 (6325–8375), n=9

0.5913

 Monocyte (/μl)

444 (308–596), n=15

430 (388–471), n=9

0.8815

Hb (g/dl)

12.4 (10.8–13.9), n=15

11.8 (10.4–13.8), n=10

0.6570

Plt (×104/μl)

30.1 (21.5–32.7), n=15

33.9 (26.6–49.4), n=10

0.0521

CRP (mg/dl)

2.8 (0.5–4.7), n=16

4.5 (1.6–8.7), n=9

0.4270

ESR (mm/h)

70 (43–104), n=12

55 (22–102), n=10

0.5977

IgG (mg/dl)

1432 (1229–1709), n=12

1597 (984–2020), n=10

0.7416

Initial PSL doses (mg)

28 (13.8–41.2), n=22

40 (15–70), n=11

0.2566

PSL doses at initial recurrence (mg)

10 (5–14), n=16

10 (6.5–12), n=9

0.9319

PSL dose reduction until initial recurrence (mg/day)

0.1 (0.03–0.4), n=15

0.03 (0.015–0.2), n=9

0.2691

Time until initial recurrence (days)

70 (26–211)

400 (294–1446)

0.0015

  1. Numbers are presented as means (SD) or medians [interquartile range: 25–75%]. The chi-square test was used for categorical variables and Wilcoxon’s rank-sum test was used for numerical variables
  2. CRP C-reactive protein, ESR erythrocyte sedimentation rate, Hb haemoglobin, IS immunosuppressant, PC prednisolone combined with immunosuppressants/biologics, Plt platelet, PM prednisolone monotherapy, PSL prednisolone, RPDAI Relapsing Polychondritis Disease Activity Index, WBC white blood cell